MELBOURNE, Australia, September 16, 2025 / Biotech Newswire / -- GAIASO is pleased to announce the appointment of Dr Tracey Brown as its new Chief Executive Officer. A highly regarded biotech entrepreneur, Dr Brown is recognised for transforming breakthrough science into real-world products, with a track record of clear strategy, collaborative leadership, and disciplined execution in resource-constrained, high-growth settings. Her appointment strengthens GAIASO’s mission to advance next-generation precision radiopharmaceuticals and deliver meaningful impact for patients.
Dr Brown brings extensive international experience across oncology and radiopharmaceutical development. She has held senior leadership roles at Telix Pharmaceuticals, Anatara Lifesciences and Alchemia, where she drove product development. Earlier, she co-founded Meditech Research, inventing the pioneering HyACT oncology drug-delivery platform and building a substantial patent estate while leading the portfolio strategy. She began her career at Monash University, where she led the Hyaluronan Laboratory and held research and adjunct appointments. Dr Brown holds a PhD in Biochemistry and Molecular Biology from Monash University and is a Graduate of the Australian Institute of Company Directors.
Dr Tracey Brown said: “I lost my mum to ovarian cancer and ever since, I’ve focused my career on translating science into real options for women and cancer patients. I’m now thrilled to lead GAIASO Theranostics, because our technology has the potential to make a real difference for patients and their families. I’m here to make sure brilliant science becomes accessible care.”
Professor Rod Hicks, Chief Medical Officer, commented: “We are delighted to welcome Tracey as GAIASO’s new CEO. Her outstanding track record in leading complex global clinical programmes, combined with her pioneering work in oncology drug development, makes her uniquely placed to guide our company into its next phase. Tracey’s vision and passion for improving patient outcomes perfectly align with GAIASO’s mission to redefine cancer care.”
About GAIASO Theranostics
GAIASO is dedicated to pioneering next-generation precision radiopharmaceuticals for women’s cancers. By combining advanced targeting with therapeutic impact, GAIASO is developing innovative solutions designed to transform the way these cancers are diagnosed and treated. With a focus on translating cutting-edge science into accessible care, the company aims to bring new hope and improved outcomes to women affected by cancer worldwide.
Contact
GAIASO Theranostics
Marketing & Communications Team
This email address is being protected from spambots. You need JavaScript enabled to view it.
Follow GAIASO on LinkedIn: www.linkedin.com/company/gaiaso-theranostics
Keywords: Female; Radiopharmaceuticals; Neoplasms; GAIASO Theranostics; Dr Tracey Brown; oncology; radiopharmaceutical development; precision radiopharmaceuticals; Meditech Research; ovarian cancer; cancer patients; oncology drug development; women’s cancers; advanced targeting; cancer diagnosis; cancer treatment;
Source: Biotech Newswire